

# Jeffrey L Dage

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3445058/publications.pdf>

Version: 2024-02-01

50  
papers

5,886  
citations

117625

34  
h-index

233421

45  
g-index

56  
all docs

56  
docs citations

56  
times ranked

4081  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , 2020, 26, 379-386.	30.7	643
2	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772.	7.4	640
3	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , 2020, 26, 387-397.	30.7	471
4	Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau and amyloid positron emission tomography. <i>Alzheimer's and Dementia</i> , 2018, 14, 989-997.	0.8	386
5	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 1683.	12.8	252
6	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021, 27, 1034-1042.	30.7	236
7	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019, 11, e11170.	6.9	228
8	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , The, 2021, 20, 739-752.	10.2	220
9	A $\beta$ 2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, eaaz2387.	10.3	202
10	Constitutive secretion of tau protein by an unconventional mechanism. <i>Neurobiology of Disease</i> , 2012, 48, 356-366.	4.4	198
11	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 149.	9.0	176
12	Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1353-1364.	0.8	160
13	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3234-3241.	7.6	150
14	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. <i>JAMA Neurology</i> , 2017, 74, 1073.	9.0	149
15	Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2022, 14, e14408.	6.9	122
16	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , 2021, 12, 3555.	12.8	115
17	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	9.0	114
18	Performance of plasma phosphorylated tau 181 and 217 in the community. <i>Nature Medicine</i> , 2022, 28, 1398-1405.	30.7	114

#	ARTICLE	IF	CITATIONS
19	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 1226-1234.	0.8	107
20	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021, 1, 114-123.	11.6	94
21	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. <i>EMBO Molecular Medicine</i> , 2021, 13, e14022.	6.9	90
22	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 198.	6.2	87
23	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. <i>Alzheimer's and Dementia</i> , 2022, 18, 1484-1497.	0.8	84
24	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A $\beta$ 42/A $\beta$ 40 and p-tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293.	0.8	72
25	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. <i>Brain</i> , 2021, 144, 2826-2836.	7.6	65
26	Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model. <i>Molecular Neurodegeneration</i> , 2018, 13, 65.	10.8	62
27	A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid- $\beta$ 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 58.	6.2	61
28	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , 2021, 97, e1681-e1694.	1.1	60
29	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	6.9	58
30	Cross-platform validation of neurotransmitter release impairments in schizophrenia patient-derived NRXN1-mutant neurons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	49
31	Pharmacological characterisation of ligand- and voltage-gated ion channels expressed in human iPSC-derived forebrain neurons. <i>Psychopharmacology</i> , 2014, 231, 1105-1124.	3.1	48
32	Site localization of sialyl Lewisx antigen on $\beta$ 1-acid glycoprotein by high performance liquid chromatography-electrospray mass spectrometry. <i>Glycobiology</i> , 1998, 8, 755-760.	2.5	42
33	Application of LC/MS and related techniques to high-throughput drug discovery. <i>Drug Discovery Today</i> , 2008, 13, 417-423.	6.4	37
34	Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. <i>Acta Neuropathologica Communications</i> , 2022, 10, 3.	5.2	36
35	Distributed Drug Discovery, Part 2: Global Rehearsal of Alkylating Agents for the Synthesis of Resin-Bound Unnatural Amino Acids and Virtual Diversity Catalog Construction. <i>ACS Combinatorial Science</i> , 2009, 11, 14-33.	3.3	35
36	Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease. <i>Movement Disorders</i> , 2021, 36, 767-771.	3.9	34

#	ARTICLE	IF	CITATIONS
37	Transcriptomic Analysis of Induced Pluripotent Stem Cells Derived from Patients with Bipolar Disorder from an Old Order Amish Pedigree. PLoS ONE, 2015, 10, e0142693.	2.5	32
38	Pharmacological Characterisation of Nicotinic Acetylcholine Receptors Expressed in Human iPSC-Derived Neurons. PLoS ONE, 2015, 10, e0125116.	2.5	29
39	Determination of Diethylpyrocarbonate-Modified Amino Acid Residues in Î±1-Acid Glycoprotein by High-Performance Liquid Chromatography Electrospray Ionizationâ€”Mass Spectrometry and Matrix-Assisted Laser Desorption/Ionization Time-of-Flightâ€”Mass Spectrometry. Analytical Biochemistry, 1998, 257, 176-185.	2.4	21
40	Distributed Drug Discovery, Part 3: Using D <sup>3</sup> Methodology to Synthesize Analogs of an Anti-Melanoma Compound. ACS Combinatorial Science, 2009, 11, 34-43.	3.3	21
41	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer's and Dementia, 2022, 18, 602-611.	0.8	20
42	Diagnostic and prognostic performance to detect Alzheimerâ€™s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimer's Research and Therapy, 2022, 14, 67.	6.2	18
43	Cross-Sectional Exploration of Plasma Biomarkers of Alzheimerâ€™s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. Journal of Clinical Medicine, 2021, 10, 1907.	2.4	15
44	Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2022, 9, 756-761.	3.7	12
45	Evidence for a Novel Pentyl Radical Adduct of the Cyclic Nitron Spin Trap MDL 101,002. Free Radical Biology and Medicine, 1997, 22, 807-812.	2.9	8
46	P3-152: Levels of TAU Protein in Plasma are Associated with Neurodegeneration and Cognitive Function in a Population-Based Elderly Cohort. , 2016, 12, P877-P878.		1
47	P4-127: Exploring the Utility of CSF Neurogranin Levels in An Alzheimerâ€™s Disease Clinical Trial. , 2016, 12, P1062-P1062.		0
48	P1â€”26: THE USE OF THE DIGITAL CLOCK DRAWING TEST (DCTCLOCKâ„„) IN THE SCREENING PHASE OF CLINICAL TRIALS FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P416.	0.8	0
49	Plasma phosphoâ€”tau217 can detect Alzheimerâ€”like pathology in Parkinsonâ€™s disease with dementia and dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e042468.	0.8	0
50	Plasma phosphoâ€”tau217 is a potential early diagnostic and prognostic biomarker of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042489.	0.8	0